Oral Submucous Fibrosis

Firstview Insight's Oropharyngeal Cancer Pipeline Review2019 provides an overview of the pipeline landscape of Oropharyngeal Cancer It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved. Oropharyngeal cancer OPC is a disease in which abnormal cells with the potential to both grow locally and spread to other parts of the body are found in the tissue of the part of the throat oropharynx that includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx.[1] The two types of oropharyngeal cancers are HPVpositive oropharyngeal cancer, which is caused by an oral human papillomavirus infection; and HPVnegative oropharyngeal cancer, which is linked to use of alcohol, tobacco, or both.The signs and symptoms of oropharyngeal cancer may include:[1][3][4] A sore throat that persists for over 2 weeks Throat pain or difficulty swallowing Unexplained rapid weight loss Voice changes more hoarse Ear pain A lump in the back of the throat or mouth A lump in the neck A dull pain behind the sternum Persistent Cough Breathing problems Hoarseness or other changes in the voice Risk factors The risk factors that can increase the risk of developing oropharyngeal cancer are:[3] Major Performing oralgenital sex on a person with a human papillomavirus HPV genital infection.[5] Smoking and chewing tobacco Heavy alcohol use Minor A diet low in fruits and vegetables Chewing betel quid, a stimulant commonly used in parts of Asia PlummerVinson syndrome Poor nutrition Asbestos exposure Certain genetic changes including: P53 mutation and CDKN2A p16 mutations.[6] Precancerous lesions Highrisk Erythroplakia Speckled erythroplakia Chronic hyperplastic candidiasis Mediumrisk Oral submucosal fibrosis Syphilitic glossitis Sideropenic dysphagia PatersonKellyBrown syndrome Lowrisk Oral lichen planus Discoid lupus erythematosus Discoid keratosis congenita Drug Profile Overview: The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information. Clinical Trial Overview: This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results. Product Development Activity: This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities. Company Overview: Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial Scope The report provides a competitive landscape The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status The report provides the list of companies which are the most active in the pipeline The report covers pipeline products based on various stages of development ranging from preregistration till discovery The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA The report summarizes all the dormant and discontinued pipeline projects The report also provides latest news for the past one year Reasons To Buy To identifying prominent players in the treatment landscape To determine the drivers; barriers and unmet need in the treatment space Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration List of products cisplatin, carboplatin taxotere, 5fluorouracil.